Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Janet Dancey

Showing results (51-60 of 71) with videos related to

Pageof 8
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2007
Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant gliomaJohn G Kuhn, Susan M Chang, Patrick Y Wen, et al.
Cancer Chemotherapy and Pharmacology|January 12, 2007
Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancerJeffrey A Meyerhardt, Jeffrey W Clark, Jeffrey G Supko, et al.
European Journal of Cancer (Oxford, England : 1990)|May 31, 2016
RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working GroupLawrence H Schwartz, Lesley Seymour, Saskia Litière, et al.
The Lancet. Oncology|March 9, 2017
iRECIST: guidelines for response criteria for use in trials testing immunotherapeuticsLesley Seymour, Jan Bogaerts, Andrea Perrone, et al.
European Journal of Cancer (Oxford, England : 1990)|May 19, 2016
RECIST 1.1-Update and clarification: From the RECIST committeeLawrence H Schwartz, Saskia Litière, Elisabeth de Vries, et al.
Eclinicalmedicine|December 31, 2024
Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trialAbha A Gupta, Anna Tinker, Derek Jonker, et al.
Nature Medicine|October 9, 2023
ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial resultsValsamo Anagnostou, Cheryl Ho, Garth Nicholas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2007
Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinibMark Agulnik, Gilda da Cunha Santos, David Hedley, et al.
Journal of Neuro-Oncology|June 30, 2009
Phase II trials of erlotinib or gefitinib in patients with recurrent meningiomaAndrew D Norden, Jeffrey J Raizer, Lauren E Abrey, et al.
Neuro-Oncology|February 13, 2010
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapyJeffrey J Raizer, Lauren E Abrey, Andrew B Lassman, et al.
Pageof 8

Showing results (51-60 of 71) with videos related to

Sort By:
Pageof 8
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2007
Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant gliomaJohn G Kuhn, Susan M Chang, Patrick Y Wen, et al.
Cancer Chemotherapy and Pharmacology|January 12, 2007
Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancerJeffrey A Meyerhardt, Jeffrey W Clark, Jeffrey G Supko, et al.
European Journal of Cancer (Oxford, England : 1990)|May 31, 2016
RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working GroupLawrence H Schwartz, Lesley Seymour, Saskia Litière, et al.
The Lancet. Oncology|March 9, 2017
iRECIST: guidelines for response criteria for use in trials testing immunotherapeuticsLesley Seymour, Jan Bogaerts, Andrea Perrone, et al.
European Journal of Cancer (Oxford, England : 1990)|May 19, 2016
RECIST 1.1-Update and clarification: From the RECIST committeeLawrence H Schwartz, Saskia Litière, Elisabeth de Vries, et al.
Eclinicalmedicine|December 31, 2024
Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trialAbha A Gupta, Anna Tinker, Derek Jonker, et al.
Nature Medicine|October 9, 2023
ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial resultsValsamo Anagnostou, Cheryl Ho, Garth Nicholas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2007
Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinibMark Agulnik, Gilda da Cunha Santos, David Hedley, et al.
Journal of Neuro-Oncology|June 30, 2009
Phase II trials of erlotinib or gefitinib in patients with recurrent meningiomaAndrew D Norden, Jeffrey J Raizer, Lauren E Abrey, et al.
Neuro-Oncology|February 13, 2010
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapyJeffrey J Raizer, Lauren E Abrey, Andrew B Lassman, et al.
Pageof 8